Pharsight

Drug Patents owned by Bayer Healthcare

1. Drug name - ALIQOPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(1 year, 7 months from now)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(7 years from now)

US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(9 years from now)

CN1688582A BAYER HEALTHCARE Fused Pyrrole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

CN100384846C BAYER HEALTHCARE Fused Pyrrole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

CN105254634A BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

CN105254634B BAYER HEALTHCARE 2, 3-Dihydro-Imidazo [1, 2-C] - Quinazoline Substituted Derivative Treating Hyperproliferative Disease And Angiogenesis-Related Disease
Dec, 2027

(5 years from now)

CN103649091A BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

CN103649091B BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

IN238818B BAYER HEALTHCARE A Fused Azolepyrimidine Compound
Sep, 2023

(11 months from now)

IN200500684P1 BAYER HEALTHCARE A Fused Azolepyrimidine Compound
Sep, 2023

(11 months from now)

IN292844B BAYER HEALTHCARE Substituted 2,3- Dihydroimidazo[1,2- C]Quinazoline Compounds
Dec, 2027

(5 years from now)

IN200902840P1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2042504A1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP1549652B1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP1549652A1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP2042504B1 BAYER HEALTHCARE Fused Azole-Pyrimidine Derivatives
Sep, 2023

(11 months from now)

EP2096919A1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2096919B1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2096919A4 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
Dec, 2027

(5 years from now)

EP2694508A1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

EP2694508B1 BAYER HEALTHCARE Substituted 2,3-Dihydroimidazo[1,2-C]Quinazoline Salts
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts Mar, 2032

(9 years from now)

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/VIAL POWDER;INTRAVENOUS Prescription

2. Drug name - NUBEQA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(13 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(13 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(15 years from now)

CN101410016B BAYER HEALTHCARE Fungicidal Compositions
Feb, 2027

(4 years from now)

CN101410016A BAYER HEALTHCARE Fungicidal Compositions
Feb, 2027

(4 years from now)

CN105061313B BAYER HEALTHCARE Androgen Receptor Modulator Compounds
Oct, 2030

(8 years from now)

CN102596910A BAYER HEALTHCARE Androgen Receptor Modulator Compounds
Oct, 2030

(8 years from now)

CN102596910B BAYER HEALTHCARE Androgen Receptor Modulator Compounds
Oct, 2030

(8 years from now)

CN105061313A BAYER HEALTHCARE Androgen Receptor Regulation Compound
Oct, 2030

(8 years from now)

IN304033B BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

IN201200848P2 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP1986495A2 BAYER HEALTHCARE Fungicidal Compositions
Feb, 2027

(4 years from now)

EP1986495B1 BAYER HEALTHCARE Fungicidal Compositions
Feb, 2027

(4 years from now)

EP3369732B1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3369732A1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3056485B1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3056485A1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP2493858B1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP2493858A1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3250554A1 BAYER HEALTHCARE A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form
Jan, 2036

(13 years from now)

EP3250554B1 BAYER HEALTHCARE A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form
Jan, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form Jan, 2036

(13 years from now)

Drugs and Companies using DAROLUTAMIDE ingredient

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

3. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(7 years from now)

US8513263 BAYER HEALTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(7 years from now)

US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(13 years from now)

US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

CN103509017B BAYER HEALTHCARE Substituted Pyrazoles As Trk Kinase Inhibitors [1, 5-A] Pyrimidine Compounds
Oct, 2029

(7 years from now)

CN103509017A BAYER HEALTHCARE As Trk Kinase Inhibitor Substituted Pyrazole And [1, 5-A] Pyrimidine Compound
Oct, 2029

(7 years from now)

CN102264736B BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

CN102264736A BAYER HEALTHCARE Substituted Pyrazole [1, 5-A] Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

CN107428760A BAYER HEALTHCARE (S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt
Nov, 2035

(13 years from now)

CN107428760B BAYER HEALTHCARE (S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form
Nov, 2035

(13 years from now)

EP2725028A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3372605A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3372605B1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028B1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071B1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463A1 BAYER HEALTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463B1 BAYER HEALTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3106463B3 BAYER HEALTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3218380B1 BAYER HEALTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

EP3218380A1 BAYER HEALTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US10047097 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US8865698 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10005783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US9447104 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10774085 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers Apr, 2037

(14 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr, 2037

(14 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr, 2037

(14 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient; Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.